Clinical Outcomes of Patients Implanted With the RxSight Light Adjustable Lens (LAL)

Withdrawn

• Conditions: Cataract; Pseudophakia

• Registration Number: NCT06488066
• Lead Sponsor: Vance Thompson Vision

Brief Summary

The objective of this investigator initiated study (IIT-002) is to collect data on commercial patients implanted with the RxSight Light Adjustable Lens (LAL).

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-13
• Primary Completion: 2022-01-01
• Study Completion: 2022-01-01
• Study First Submitted: 2024-05-16
• Status Verified: 2024-07
• Study First Submitted QC: 2024-07-03
• Last Update Submitted: 2024-07-03
• Study First Posted: 2024-07-05
• Last Update Posted: 2024-07-05

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Sign a written Informed Consent Document
• Implanted commercially with the LAL and completed LDD light treatments

Exclusion Criteria

• Previous corneal or intraocular surgery other than removal of cataract and implantation of the LAL

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Manifest refraction	Pre operatively and immediately post operatively	A qualified ophthalmologist, optometrist, or a trained ophthalmic technician should obtain the refraction, in 0.25D steps, in a calibrated refraction lane. If the subject has a current pair of glasses for distance vision, they can be measured with a lensometer, and these measurements are used as the beginning approximate refraction

Trial Locations

Locations (1)

Vance Thompson Vision; 🇺🇸 Sioux Falls, South Dakota, United States